Translation and Commercialisation
Our translation and commercialisation office works closely with Centenary scientists to progress research discoveries towards the development of new treatments. Centenary actively engages with pharmaceutical and biotech companies, investors and other academic collaborators globally.
Innovations
Centenary strives to deliver improved health outcomes to patients. Centenary’s research expertise, capabilities and discoveries span a wide range of areas and indications.
Centre: Healthy Ageing
Indication: Alzheimer’s disease
Stage: Preclinical
Description: Therapy targeting a novel mechanism
Status: Licensed. Open to investment.
Centre: Infection & Immunity
Indication: COVID
Stage: Preclinical
Description: Novel composition and formulation
Status: Available to licence
Centre: Cancer Innovations
Indication: Diagnostic – aggressive cancers
Stage: Phase 1
Description: A novel tumour imaging agent for rapid assessment of treatment response
Status: Licensed
Centre: Rare Diseases & Gene Therapy
Indication: Genetic diseases
Stage: Preclinical
Description: Platform technology to increase efficiency and safety, and reduce cost of AAV gene therapies
Status: Available for licensing or investment via start-up AAVec Bio
Centre: Biomedical AI
Indication: Broad application
Stage:
Description: Directed evolution system to rapidly optimise selected properties of biologics
Status: Seeking collaborations
Centre: Rare Diseases & Gene Therapy
Indication: Broad application
Stage:
Description: Direct & quantifiable measurement of small molecule-target engagement
Status: Seeking collaborations
Centre: Infection & Immunity
Indication: Tuberculosis
Stage: Preclinical
Description: Novel compositions. Large head-2-head study of a range of antigens & adjuvants to select optimal composition
Status: Seeking investment
Contact
For enquires, contact:
Dr Katrina Frankcombe
Translation and Commercialisation Manager
Email: k.frankcombe@centenary.org.au
Phone: +61 2 9565 6266.